Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135228589> ?p ?o ?g. }
- W3135228589 endingPage "39" @default.
- W3135228589 startingPage "28" @default.
- W3135228589 abstract "Actuality One of the most widely discussed treatments for patients with COVID-19, especially at the beginning of the epidemy, was the use of the antimalarial drug hydroxychloroquine (HCQ). The first small non-randomized trials showed the ability of HCQ and its combination with azithromycin to accelerate the elimination of the virus and ease the acute phase of the disease. Later, large, randomized trials did not confirm it (RECOVERY, SOLIDARITY). This study is a case-control study in which we compared patients who received and did not receive HCQ. Material and Methods 103 patients (25 in the HCQ treatment group and 78 in the control group) with confirmed COVID-19 (SARS-CoV-2 virus RNA was detected in 26 of 73 in the control group (35.6%) and in 10 of 25 (40%) in the HCQ group) and in the rest - a typical picture of viral pneumonia on multislice computed tomography [MSCT]) were included in the analysis. The severity of lung damage was limited to stages I-II, the CRP level should not exceed 60 mg/dL, and oxygen saturation in the air within 92-98%. We planned to analysis the duration of treatment of patients in the hospital, the days until the normalization of body temperature, the number of points according to the original SHOCS-COVID integral scale, and changes in its components (C-reactive protein (CRP), D-dimer, and the percentage of lung damage according to MSCT). Results Analysis for the whole group revealed a statistically significant increase in the time to normalization of body temperature from 4 to 7 days (by 3 days, p<0.001), and the duration of hospitalization from 9.4 to 11.8 days (by 2.4 days, p=0.002) when using HCQ in comparison with control. Given the incomplete balance of the groups, the main analysis included 46 patients who were matched by propensity score matching. The trend towards similar dynamics continued. HCQ treatment slowed down the time to normalization of body temperature by 1.8 days (p=0.074) and lengthened the hospitalization time by 2.1 days (p=0.042). The decrease in scores on the SHOCS -COVID scale was statistically significant in both groups, and there were no differences between them (delta - 3.00 (2.90) in the HCQ group and - 2.69 (1.55) in control, p=0.718). At the same time, in the control group, the CRP level returned to normal (4.06 mg/dl), and with the use of GC, it decreased but remained above the norm (6.21 mg/dl, p=0.05). Side effects requiring discontinuation of treatment were reported in 3 patients in the HCQ group and none in the control group. Conclusion We have not identified any positive properties of HCQ and its ability to influence the severity of COVID-19. This antimalarial agent slows down the normalization of the body's inflammatory response and lengthens the time spent in the hospital. HCQ should not be used in the treatment of COVID-19." @default.
- W3135228589 created "2021-03-15" @default.
- W3135228589 creator A5001292864 @default.
- W3135228589 creator A5004639592 @default.
- W3135228589 creator A5005131515 @default.
- W3135228589 creator A5010481003 @default.
- W3135228589 creator A5021438641 @default.
- W3135228589 creator A5025244705 @default.
- W3135228589 creator A5031796667 @default.
- W3135228589 creator A5081014343 @default.
- W3135228589 creator A5086255732 @default.
- W3135228589 date "2021-02-28" @default.
- W3135228589 modified "2023-09-27" @default.
- W3135228589 title "Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study" @default.
- W3135228589 cites W2095807050 @default.
- W3135228589 cites W2169254657 @default.
- W3135228589 cites W2744864906 @default.
- W3135228589 cites W2991611679 @default.
- W3135228589 cites W3004674056 @default.
- W3135228589 cites W3005212621 @default.
- W3135228589 cites W3007201727 @default.
- W3135228589 cites W3009912996 @default.
- W3135228589 cites W3010930696 @default.
- W3135228589 cites W3011147220 @default.
- W3135228589 cites W3012529899 @default.
- W3135228589 cites W3013174684 @default.
- W3135228589 cites W3020239101 @default.
- W3135228589 cites W3022358203 @default.
- W3135228589 cites W3023082818 @default.
- W3135228589 cites W3023221016 @default.
- W3135228589 cites W3023346879 @default.
- W3135228589 cites W3025972894 @default.
- W3135228589 cites W3027680906 @default.
- W3135228589 cites W3039915417 @default.
- W3135228589 cites W3041240655 @default.
- W3135228589 cites W3044118599 @default.
- W3135228589 cites W3044416430 @default.
- W3135228589 cites W3045150146 @default.
- W3135228589 cites W3081644165 @default.
- W3135228589 cites W3091868035 @default.
- W3135228589 cites W3092654917 @default.
- W3135228589 cites W3093765994 @default.
- W3135228589 cites W3096942772 @default.
- W3135228589 cites W3102453076 @default.
- W3135228589 cites W3105781131 @default.
- W3135228589 cites W3112929063 @default.
- W3135228589 doi "https://doi.org/10.18087/cardio.2021.2.n1548" @default.
- W3135228589 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33734044" @default.
- W3135228589 hasPublicationYear "2021" @default.
- W3135228589 type Work @default.
- W3135228589 sameAs 3135228589 @default.
- W3135228589 citedByCount "0" @default.
- W3135228589 crossrefType "journal-article" @default.
- W3135228589 hasAuthorship W3135228589A5001292864 @default.
- W3135228589 hasAuthorship W3135228589A5004639592 @default.
- W3135228589 hasAuthorship W3135228589A5005131515 @default.
- W3135228589 hasAuthorship W3135228589A5010481003 @default.
- W3135228589 hasAuthorship W3135228589A5021438641 @default.
- W3135228589 hasAuthorship W3135228589A5025244705 @default.
- W3135228589 hasAuthorship W3135228589A5031796667 @default.
- W3135228589 hasAuthorship W3135228589A5081014343 @default.
- W3135228589 hasAuthorship W3135228589A5086255732 @default.
- W3135228589 hasBestOaLocation W31352285891 @default.
- W3135228589 hasConcept C126322002 @default.
- W3135228589 hasConcept C168563851 @default.
- W3135228589 hasConcept C2777648638 @default.
- W3135228589 hasConcept C2777914695 @default.
- W3135228589 hasConcept C2778836808 @default.
- W3135228589 hasConcept C2778907293 @default.
- W3135228589 hasConcept C2779123688 @default.
- W3135228589 hasConcept C2779134260 @default.
- W3135228589 hasConcept C3008058167 @default.
- W3135228589 hasConcept C501593827 @default.
- W3135228589 hasConcept C524204448 @default.
- W3135228589 hasConcept C71924100 @default.
- W3135228589 hasConcept C86803240 @default.
- W3135228589 hasConcept C89423630 @default.
- W3135228589 hasConcept C90924648 @default.
- W3135228589 hasConceptScore W3135228589C126322002 @default.
- W3135228589 hasConceptScore W3135228589C168563851 @default.
- W3135228589 hasConceptScore W3135228589C2777648638 @default.
- W3135228589 hasConceptScore W3135228589C2777914695 @default.
- W3135228589 hasConceptScore W3135228589C2778836808 @default.
- W3135228589 hasConceptScore W3135228589C2778907293 @default.
- W3135228589 hasConceptScore W3135228589C2779123688 @default.
- W3135228589 hasConceptScore W3135228589C2779134260 @default.
- W3135228589 hasConceptScore W3135228589C3008058167 @default.
- W3135228589 hasConceptScore W3135228589C501593827 @default.
- W3135228589 hasConceptScore W3135228589C524204448 @default.
- W3135228589 hasConceptScore W3135228589C71924100 @default.
- W3135228589 hasConceptScore W3135228589C86803240 @default.
- W3135228589 hasConceptScore W3135228589C89423630 @default.
- W3135228589 hasConceptScore W3135228589C90924648 @default.
- W3135228589 hasIssue "2" @default.
- W3135228589 hasLocation W31352285891 @default.
- W3135228589 hasOpenAccess W3135228589 @default.
- W3135228589 hasPrimaryLocation W31352285891 @default.
- W3135228589 hasRelatedWork W2050197160 @default.